-

PerkinElmer Launches Solus Listeria monocytogenes ELISA Assay for Testing Across Food and Environmental Samples

Solution Receives AOAC® PTM SM Certification

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today launched the PerkinElmer Solus Listeria monocytogenes ELISA Assay. This new offering will help high throughput food processors and contract labs focus on L. mono testing for food and environmental surface samples. In sync with leading industry standards, the new solution is being introduced with Performance Tested Method SM (PTM) certification from AOAC® INTERNATIONAL (Association of Official Analytical Collaboration).

Though Listeria makes fewer people sick than other foodborne pathogens, the presence of the bacteria is more pervasive and Listeriosis carries a 20 – 30%* mortality rate if contracted by pregnant women, those over 65, or people with compromised immune systems (*Source: https://www.who.int/ith/diseases/listeriosis/en/.)

The PerkinElmer Solus L. mono assay detects this harmful bacteria with accuracy, specificity and convenience, especially for geographic regions whose regulations require separate reporting for L. mono.

Simplifying workflows, the new assay features the ability to employ a single protocol for both food samples (such as unpasteurized cheeses, meats, shrimp and vegetables) as well as environmental sample swabs and sponges. A simple 24 hour + 24 hour enrichment process leverages supplemented standard media and incubation parameters are shared across matrices. Users can choose to process samples manually or automate them with Dynex Technologies’ DS-2® system.

“Listeria is a concern for food processors and consumers because it can live anywhere and can create lethal illness,” said Greg Sears, Vice President and General Manager, Food, PerkinElmer. “Our new Solus L. mono assay with AOAC PTM certification helps labs and processors be even more vigilant and precise in detecting and fighting back against this challenge to the global food chain.”

The new Solus L. mono assay, joins PerkinElmer’s foodborne pathogen portfolio including the wider spectrum Solus One Listeria assay, Solus One Salmonella, and Solus E. coli O157 ELISA. These innovations are part of the company’s broader food safety and quality solutions for grain, dairy, meats, produce, edible oils, seafood, and cannabis. For more information please visit www.perkinelmer.com/category/food-safety-quality.

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Contacts

Jennifer McNeil
+1 508 361-5901
Jennifer.mcneil@perkinelmer.com

PerkinElmer, Inc.

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Summary
The new PerkinElmer Solus Listeria monocytogenes ELISA Assay focuses on L. mono testing for food and environmental surface safety.
Release Versions

Contacts

Jennifer McNeil
+1 508 361-5901
Jennifer.mcneil@perkinelmer.com

More News From PerkinElmer, Inc.

Revvity to Present at J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 44th annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT. President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities. To access the presentation, a live audio webcast will be available on the Events section of the Company’s website. A replay of the presentation will be posted on the Revvity Investor Relations website after...

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to acce...

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: UBS Global Healthcare Conference 2025 Monday, November 10, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Jefferies 2025 London Healthcare Conference Tuesday, November 18, 2025 2:00 p.m. GMT – Max Krakowiak Citi's 2025 Global Healthcare Conference Tuesday, December 2, 2025 9:00 a.m. ET – Prahlad Singh, president and chief execu...
Back to Newsroom